Buy Anti-Ipilimumab ELISA Kit

Catalog No.

KAD17201

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative sandwich enzyme immunoassay technique. Ipilimumab has been pre-coated onto a microplate. Samples or standards are pipetted into microwells and Anti-Ipilimumab will be captured by immobilized Ipilimumab. After washing away any unbound substances, a biotin-labeled Ipilimumab is added to the wells. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of Anti-Ipilimumab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Anti-Ipilimumab concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

7.81 - 500 ng/mL

Sensitivity

4.25 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <10%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <15%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

	Intra-Assay Precision			Inter-Assay Precision
Sample	1	2	3	1	2	3
n	16	16	16	24	24	24
Mean (ng/mL)	223.4	60.7	11.8	225.5	49.1	12.8
Standard deviation	14.0	3.3	1.1	14.9	2.8	1.0
CV (%)	6.3	5.5	9.0	6.6	5.7	8.2

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.

Alternative Names

BMS-734016,MDX-010,MDX-CTLA-4,CAS: 477202-00-9

Experiment Example

CALCULATION OF RESULTS
Average the duplicate readings for each standard and sample. Construct a standard curve by plotting the mean absorbance for each standard on the Y-axis against the concentration on the X-axis and draw a best fit curve through the points on the graph. The data may be linearized by plotting the log of the Anti-Ipilimumab concentrations versus the log of the O.D. and the best fit line can be determined by regression analysis. This procedure will produce an adequate but less precise fit of the data. If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.

Impaired Overall Survival of Melanoma Patients Due to Antibiotic Use Prior to Immune Checkpoint Inhibitor Therapy: Systematic Review and Meta-Analysis., PMID:40507352

Immune Checkpoint Inhibitors in the Treatment of Advanced Melanoma in Older Patients: An Overview of Published Data., PMID:40507314

Gender and age disparities in cardiac immune-related adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FAERS database., PMID:40506075

Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study., PMID:40505525

NEXUS: a phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies., PMID:40502306

Biomarker analysis and treatment dynamics following preoperative ipilimumab plus nivolumab in locally advanced urothelial cancer from the phase 1B NABUCCO study., PMID:40489082

Organ-Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study., PMID:40488227

CTLA-4 blockade in ovarian cancer immunotherapy: Mechanisms and clinical strategies., PMID:40482550

Cost-Utility and Budget Impact Analysis of Immunotherapy for First-Line Treatment of Advanced Kidney Cancer in Latin America: Evidence From Uruguay., PMID:40482312

A phase II study of nivolumab, ipilimumab, and radiation in combination with influenza vaccine in patients with pancreatic cancer (INFLUENCE)., PMID:40475164

Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial., PMID:40474841

Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic Non-small Cell Lung Cancer Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1., PMID:40473108

Immune-mediated enterocolitis is associated with immune checkpoint inhibitors: A pharmacovigilance study from the FDA Adverse Event Reporting System (FAERS) database., PMID:40465755

Malignant mesothelioma with a novel BAP1 germline frameshift mutation treated with dual immune checkpoint inhibitors: A case report., PMID:40463358

Primary Vaginal Melanoma or Clear Cell Sarcoma: A Difficult Differential Diagnosis., PMID:40462828

Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade., PMID:40460830

Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study., PMID:40449497

Clinical Management and Outcomes of Immune-Related Adverse Events During Treatment with Immune Checkpoint Inhibitor Therapies in Melanoma and Renal Cell Carcinoma: A UK Real-World Evidence Study., PMID:40448748

Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA., PMID:40446626

Long-term real-world outcomes of nivolumab plus ipilimumab for advanced renal cell carcinoma: a minimum of 4-years follow-up study., PMID:40446096

The promise of PD1/PDL1 targeted immunotherapy in locally advanced cervical cancer: a game-changer for patients outcome?, PMID:40433369

Correlation Between Body Mass Index and Clinical Outcomes in Advanced Renal Cell Carcinoma Patients., PMID:40425321

Using liquid biopsies to guide treatment and monitor response in BRAF V600E positive adenocarcinoma of unknown primary., PMID:40425210

Spontaneous Dramatic Regression of Clear Cell Renal Cell Carcinoma After Pazopanib-Induced Severe Systemic Inflammatory Syndrome: A Case Report and Literature Review., PMID:40422519

Multisystem immune-related adverse reactions with immune checkpoint inhibitors., PMID:40421943

Looking Toward the Future: Emerging Therapies for Hepatocellular Carcinoma., PMID:40416920

Case Report: Acral vasculitis induced by Immune Checkpoint Inhibitors: a case series and literature review., PMID:40416866

The Importance of Timing in Immunotherapy: A Systematic Review., PMID:40416194

Adjuvant Immunotherapy in Microsatellite Instability-High Colon Cancer: A Literature Review on Efficacy, Challenges, and Future Directions., PMID:40415356

Systemic Therapy for Melanoma: What Surgeons Need to Know., PMID:40413004

A treatment-related death predictive score for treatment-naïve advanced non-small cell lung cancer., PMID:40409025

A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort., PMID:40402690

Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-Risk Melanoma., PMID:40392969

Real-world efficacy and safety of nivolumab and ipilimumab in metastatic renal cell carcinoma: a Polish multicenter study., PMID:40391586

Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial., PMID:40389374

Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL study., PMID:40389373

Metabolic tumor volume on 18F-FDG uptake as a negative predictor after ipilimumab plus nivolumab in advanced non-small cell lung cancer., PMID:40386730

Breaking Through: Immunotherapy Innovations in Pleural Mesothelioma., PMID:40382268

Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer., PMID:40378356

[Renal injury during combination immunotherapy (ipilimumab + nivolumab) in patients with metastatic renal cell cancer who previously underwent nephrectomy]., PMID:40377638

Exceptional Response in a Patient with mRCC Through Precision-Guided Treatment Involving Immunotherapy Rechallenge with Temsirolimus and Bevacizumab., PMID:40376550

Association of Sinonasal Symptoms and Disease With Immune Checkpoint Inhibitor Therapy., PMID:40370338

Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: A Single-Center Experience of Biopsy-Proven Cases., PMID:40364262

Haematological toxicities with immune checkpoint inhibitors in digestive system tumors: a systematic review and network meta-analysis of randomized controlled trials., PMID:40360867

Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)., PMID:40360544

An Extremely Rare Case of Immune Checkpoint Inhibitors-Related Hypoparathyroidism and a Critical Literature Review., PMID:40356787

Accelerated atherosclerosis associated with immune checkpoint inhibitors: a systematic review and meta-analysis of pre-clinical studies., PMID:40354680

Adverse neurologic events of immune checkpoint inhibitor monotherapy vs. combination therapy for melanoma., PMID:40351833

Nivolumab plus ipilimumab in hepatocellular carcinoma., PMID:40349715

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial., PMID:40349714

Document Download

Anti-Ipilimumab ELISA Kit.pdf

Anti-Ipilimumab ELISA Kit